Health-Tech & AI Startups
From prototype to procurement-ready
Independent validation, fractional clinical leadership and a credible route to NHS adoption — matched to your stage.
By stage
What you need, when you need it
Seed
Intended-use definition, evidence roadmap, clinical sanity-check.
Series A
Clinical validation, safety case, DTAC preparation.
Growth
Procurement readiness, pilots and market access.
Mapped services
How we help
AI Validation & Clinical Safety →
Independent evaluation and assurance.
Startup Clinical Advisory →
Fractional clinical leadership.
NHS Pilot Design →
Pilots with metrics and a path to scale.
NHS Buyer Readiness →
The evidence buyers expect.
The wall founders hit
Great technology is not the same as a buyable product
Most health-tech and clinical-AI startups are built by strong engineering and commercial teams who can ship quickly, but who discover late that the NHS does not buy on product capability alone. The moment a real procurement conversation begins, the questions change: where is the independent evidence that this is safe, what is the clinical risk management behind it, how does special-category data flow, and who is accountable if something goes wrong. Without senior clinical input in the room, founders end up guessing at the answers — and guessing wrong is expensive when a pilot stalls in information governance for months.
The second trap is building evidence in the wrong order. Teams often invest in a polished trial or a glossy white paper before they have written down a precise intended-use statement, which means the evidence does not actually map to the claim a buyer cares about. We help you sequence this correctly — define the intended use first, then build only the validation and clinical-safety evidence that claim requires, so you spend scarce runway on proof that converts.
Working with us
Senior clinical depth without a senior clinical salary
We typically work directly with founders, CTOs and heads of clinical or product. For an early team that means fractional clinical advisory and office hours that turn open clinical questions into clear decisions. As you mature, it means an independent validation report you can put in front of a trust, a clinical-safety case for your software as a medical device, and a pilot designed to produce the metrics your next funding round and your first reference customer will both demand.
We are an advisor, not a regulatory agent. We help you build the clinical evidence and assurance buyers expect, and we work alongside your own regulatory consultants on formal conformity assessment and UKCA marking — being explicit about that boundary is part of why our work holds up under scrutiny. When you are ready, NHS buyer readiness pulls the whole evidence pack together.
Answers
Frequently asked questions
We are pre-revenue — is this for us?
Yes. We match support to your stage, from intended-use definition and an evidence roadmap at seed, to validation and procurement readiness as you approach NHS pilots.
Can you be our fractional clinical lead?
Yes — fractional clinical advisory and founder office-hours give you senior clinical input without a full-time hire. See Startup Clinical Advisory.
How do we get NHS-ready?
We help you assemble DTAC, clinical safety and DPIA evidence buyers expect. See NHS Buyer Readiness.
Will working with you help with our fundraise?
Indirectly, yes. Investors increasingly probe clinical risk, regulatory pathway and evidence quality during diligence. An independent validation report, a defined intended-use statement and a credible evidence roadmap demonstrate that you have de-risked the parts of the business technical founders often underestimate.
Do you take equity instead of fees?
Our engagements are fee-based and independent. Keeping our advisory at arm's length is what makes our validation credible to NHS buyers and investors — a report from an advisor with a stake in the outcome carries far less weight.
Book founder office hours
Tell us your stage and challenge; we'll propose a starting package.